Phase I, First-In-Human Study of TT-00920 in Healthy Subjects
Status:
Active, not recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
This is a first-in-human, randomized, double-blind, placebo-controlled study. The primary
objectives of the study were to investigate the safety and tolerability and determine the PK
profiles of single ascending doses (SAD) of TT-00920 administered to healthy subjects. The
secondary objectives of the study were to assess the effect of food on the PK of TT-00920
following an oral dose.
Phase:
Phase 1
Details
Lead Sponsor:
TransThera Biosciences Co., Ltd TransThera Sciences (Nanjing), Inc.